Cellectis SA（CLLS）財務資料CLLSCellectis SA

Cellectis SA (CLLS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Therapeutics, accounting for 99.2% of total sales, equivalent to $5.56M. Another important revenue stream is Plants. Understanding this composition is critical for investors evaluating how CLLS navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Cellectis SA maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -336.89%, while the net margin is -273.90%. These profitability ratios, combined with a Return on Equity (ROE) of -94.54%, provide a clear picture of how effectively CLLS converts its operational activities into shareholder value.

In the context of the broader market, CLLS competes directly with industry leaders such as CING and ACRV. With a market capitalization of $109.80M, it holds a leading position in the sector. When comparing efficiency, CLLS's gross margin of 100.00% stands against CING's N/A and ACRV's N/A. Such benchmarking helps identify whether Cellectis SA is trading at a premium or discount relative to its financial performance.

Cellectis reported a gross margin of only 21.50% in Q1 2026, down from 93.30% in Q3 2025, indicating deteriorating profitability. The company also has a high debt-to-equity ratio of 181.25%, raising concerns about financial stability.